Literature DB >> 8650190

Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator.

T H Bugge1, M J Flick, M J Danton, C C Daugherty, J Romer, K Dano, P Carmeliet, D Collen, J L Degen.   

Abstract

The availability of gene-targeted mice deficient in the urokinase-type plasminogen activator (uPA), urokinase receptor (uPAR), tissue-type plasminogen activator (tPA), and plasminogen permits a critical, genetic-based analysis of the physiological and pathological roles of the two mammalian plasminogen activators. We report a comparative study of animals with individual and combined deficits in uPAR and tPA and show that these proteins are complementary fibrinolytic factors in mice. Sinusoidal fibrin deposits are found within the livers of nearly all adult mice examined with a dual deficiency in uPAR and tPA, whereas fibrin deposits are never found in livers collected from animals lacking uPAR and rarely detected in animals lacking tPA alone. This is the first demonstration that uPAR has a physiological role in fibrinolysis. However, uPAR-/-/tPA-/- mice do not develop the pervasive, multi-organ fibrin deposits, severe tissue damage, reduced fertility, and high morbidity and mortality observed in mice with a combined deficiency in tPA and the uPAR ligand, uPA. Furthermore, uPAR-/-/tPA-/- mice do not exhibit the profound impairment in wound repair seen in uPA-/-/tPA-/- mice when they are challenged with a full-thickness skin incision. These results indicate that plasminogen activation focused at the cell surface by uPAR is important in fibrin surveillance in the liver, but that uPA supplies sufficient fibrinolytic potential to clear fibrin deposits from most tissues and support wound healing without the benefit of either uPAR or tPA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8650190      PMCID: PMC39159          DOI: 10.1073/pnas.93.12.5899

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Molecular cloning of complementary DNA to mouse tissue plasminogen activator mRNA and its expression during F9 teratocarcinoma cell differentiation.

Authors:  R J Rickles; A L Darrow; S Strickland
Journal:  J Biol Chem       Date:  1988-01-25       Impact factor: 5.157

Review 2.  Paroxysmal nocturnal hemoglobinuria.

Authors:  B Rotoli; L Luzzatto
Journal:  Semin Hematol       Date:  1989-07       Impact factor: 3.851

3.  Tissue cooperation in a proteolytic cascade activating human interstitial collagenase.

Authors:  C S HE; S M Wilhelm; A P Pentland; B L Marmer; G A Grant; A Z Eisen; G I Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

4.  Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-beta to TGF-beta.

Authors:  L E Odekon; F Blasi; D B Rifkin
Journal:  J Cell Physiol       Date:  1994-03       Impact factor: 6.384

5.  Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse.

Authors:  L Ossowski; H Russo-Payne; E L Wilson
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

6.  Localization of urokinase-type plasminogen activator messenger RNA in the normal mouse by in situ hybridization.

Authors:  P Kristensen; J Eriksen; K Danø
Journal:  J Histochem Cytochem       Date:  1991-03       Impact factor: 2.479

7.  Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds.

Authors:  J Rømer; L R Lund; J Eriksen; E Ralfkiaer; R Zeheb; T D Gelehrter; K Danø; P Kristensen
Journal:  J Invest Dermatol       Date:  1991-11       Impact factor: 8.551

8.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease.

Authors:  C T Guy; R D Cardiff; W J Muller
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

9.  The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes.

Authors:  A Estreicher; J Mühlhauser; J L Carpentier; L Orci; J D Vassalli
Journal:  J Cell Biol       Date:  1990-08       Impact factor: 10.539

10.  In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion.

Authors:  L Ossowski; G Clunie; M T Masucci; F Blasi
Journal:  J Cell Biol       Date:  1991-11       Impact factor: 10.539

View more
  64 in total

1.  Migration of keratinocytes through tunnels of digested fibrin.

Authors:  V Ronfard; Y Barrandon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

Review 2.  New thrombolytic strategy: bolus administration of tPA and urokinase-fibrinogen conjugate.

Authors:  A V Maksimenko; E G Tischenko
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

3.  The Oral Serine Protease Inhibitor WX-671 - First Experience in Patients with Advanced Head and Neck Carcinoma.

Authors:  Jens E Meyer; Carsten Brocks; Hendrik Graefe; Carola Mala; Natalie Thäns; Markus Bürgle; Annette Rempel; Nicole Rotter; Barbara Wollenberg; Stephan Lang
Journal:  Breast Care (Basel)       Date:  2008-10-16       Impact factor: 2.860

4.  Dissecting the urokinase activation pathway using urokinase-activated anthrax toxin.

Authors:  Shihui Liu; Thomas H Bugge; Arthur E Frankel; Stephen H Leppla
Journal:  Methods Mol Biol       Date:  2009

Review 5.  The endothelial cell annexin A2 system and vascular fibrinolysis.

Authors:  MaryAnn Dassah; Arun B Deora; Kaili He; Katherine A Hajjar
Journal:  Gen Physiol Biophys       Date:  2009       Impact factor: 1.512

6.  Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.

Authors:  Kasper Almholt; Ole Didrik Lærum; Boye Schnack Nielsen; Ida Katrine Lund; Leif Røge Lund; John Rømer; Annika Jögi
Journal:  Clin Exp Metastasis       Date:  2015-06-04       Impact factor: 5.150

7.  Plasmin inhibition increases MMP-9 activity and decreases vein wall stiffness during venous thrombosis resolution.

Authors:  Nicholas A Dewyer; Vikram Sood; Erin M Lynch; Catherine E Luke; Gilbert R Upchurch; Thomas W Wakefield; Steven Kunkel; Peter K Henke
Journal:  J Surg Res       Date:  2007-06-14       Impact factor: 2.192

8.  Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.

Authors:  Elaine M Sloand; Loretta Pfannes; Phillip Scheinberg; Kenneth More; Colin O Wu; McDonald Horne; Neal S Young
Journal:  Exp Hematol       Date:  2008-10-26       Impact factor: 3.084

9.  The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.

Authors:  Niels Behrendt; Karin List; Peter A Andreasen; Keld Danø
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

10.  Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice.

Authors:  Rikke Stagaard; Carsten Dan Ley; Kasper Almholt; Lisbeth Høier Olsen; Tom Knudsen; Matthew J Flick
Journal:  Blood Adv       Date:  2018-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.